Laverock Therapeutics, established in 2021 to commercialise the gene editing induced gene silencing (GEiGS^®) platform for all human therapeutic applications, has expanded its seed funding round to £13.5M. This investment was led by Calculus Capital with additional participation by Eli Lilly and Company, Mercia Ventures, Maven Capital Partners, Eos, UK Innovation & Science Seed Fund and Tekfen Ventures.